Cargando…

Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment

Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Ye Jin, Hwang, Hyung Bin, Chung, Sung Kun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Ophthalmological Society 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958635/ https://www.ncbi.nlm.nih.gov/pubmed/24688262 http://dx.doi.org/10.3341/kjo.2014.28.2.177

Ejemplares similares

Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab
por: Britton, Anna Krystyna, et al.
Publicado: (2020)

The Effect of Bevacizumab versus Ranibizumab in the Treatment of Corneal Neovascularization: A Preliminary Study
por: Kim, Jin-Hyoung, et al.
Publicado: (2013)

The Effect of Bevacizumab on Corneal Neovascularization in Rabbits
por: Kim, Wung-Jae, et al.
Publicado: (2010)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
por: Al-Debasi, Tariq, et al.
Publicado: (2017)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes
por: Sarah, Belghmaidi, et al.
Publicado: (2016)

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab
por: Krizova, Deli, et al.
Publicado: (2014)

Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab
por: Hwang, Duck Jin, et al.
Publicado: (2012)

Successful regression of newly formed corneal neovascularization by subconjunctival injection of bevacizumab in patients with chemical burns
por: Peng, Wen-yan, et al.
Publicado: (2023)

Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
por: Karagiannis, Dimitrios, et al.
Publicado: (2017)

Regression of Iris Neovascularization after Subconjunctival Injection of Bevacizumab
por: Ryoo, Na Kyung, et al.
Publicado: (2013)

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
por: Merz, Patrick R., et al.
Publicado: (2018)

Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study
por: Cha, Dong Min, et al.
Publicado: (2014)

Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Neovascular Events in Eyes with Central Retinal Vein Occlusion Undergoing Serial Bevacizumab or Ranibizumab Intravitreal Injections: A Retrospective Review
por: DeCroos, Francis Char, et al.
Publicado: (2014)

Human Herpesvirus-6 corneal Endotheliitis after intravitreal injection of Ranibizumab
por: Onda, Masahiro, et al.
Publicado: (2019)

Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
por: Canut, MI, et al.
Publicado: (2011)

A Case of Intravitreal Bevacizumab Injection for the Treatment of Choroidal Neovascularization in Angioid Streaks
por: Lee, Ji Woong, et al.
Publicado: (2011)

Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
por: Ellabban, Abdallah A, et al.
Publicado: (2012)

Single intravitreal ranibizumab for myopic choroidal neovascularization
por: Nor-Masniwati, Saidin, et al.
Publicado: (2011)

Antiproliferative, Apoptotic, and Autophagic Activity of Ranibizumab, Bevacizumab, Pegaptanib, and Aflibercept on Fibroblasts: Implication for Choroidal Neovascularization
por: Lytvynchuk, Lyubomyr, et al.
Publicado: (2015)

Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia
por: Rishi, Pukhraj, et al.
Publicado: (2011)

Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
por: Mansour, Ahmad M, et al.
Publicado: (2012)

Multiple Intravitreal Ranibizumab Injections for Persistant Choroidal Neovascularization Associated with Presumed Ocular Histoplasmosis Syndrome
por: Yılmaz, Turgut, et al.
Publicado: (2017)

Temporary Vitelliform Regression After Intravitreal Ranibizumab Injection for Macular Neovascularization Complicating Best Disease
por: Fayed, Alaa
Publicado: (2022)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Electrophysiologic changes after intravitreal ranibizumab injection for the treatment of choroidal neovascular membrane (CNVM)
por: Bhurayanontachai, Patama, et al.
Publicado: (2011)

Lasting Controversy on Ranibizumab and Bevacizumab
por: Zou, Lihui, et al.
Publicado: (2011)

Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
por: Kodjikian, Laurent, et al.
Publicado: (2014)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
por: Biswas, Partha, et al.
Publicado: (2011)

Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: a case report
por: Iannetti, Ludovico, et al.
Publicado: (2013)

Choroidal Osteoma and Secondary Choroidal Neovascularization Treated with Ranibizumab
por: Sarıgül Sezenöz, Almila, et al.
Publicado: (2017)

Corneal thinning following bevacizumab intrastromal injection for the treatment of idiopathic lipid keratopathy
por: Sun, Kristie J., et al.
Publicado: (2022)

Intravitreal bevacizumab as therapy for refractory neovascular glaucoma secondary to iris metastasis of breast carcinoma
por: Vale, Stephanie, et al.
Publicado: (2018)

Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization
por: Dratviman-Storobinsky, Olga, et al.
Publicado: (2009)

Surgically Induced Corneal Astigmatism Following Intravitreal Ranibizumab Injection
por: Kocatürk, Tolga, et al.
Publicado: (2015)

Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats
por: Hashemian, Mohammad Nasser, et al.
Publicado: (2017)

Intravitreal ranibizumab for treatment of choroidal neovascularization secondary to a bilateral choroidal osteoma
por: Zafar, Sidra, et al.
Publicado: (2016)

Mechanisms Controlling the Effects of Bevacizumab (Avastin) on the Inhibition of Early but Not Late Formed Corneal Neovascularization
por: Chen, Wei-Li, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4i4k303dq69g7guho6sh690ojj